Progression of PD?1/PD?L1 inhibitors and renal cell carcinoma immunothreapy
ZHANG Xiaomin
HU Hong
PAN Hongming
Abstract：New therapeutic methods for renal carcinoma are in urgent need because of its insensitivity to the existing treat?ments, radiotherapy and chemotherapy. Programmed cell death factor 1 ( PD?1) and programmed cell death factor ligand 1 ( PD?L1) are costimulatory factors. Anti?PD?1 and anti?PD?L1 therapies are proved to be effective among the treatments for malignant melanoma and non?small cell lung cancer. Moreover, they are widely used to other malignancies as well. PD?1/PD?L1 inhibitors are expected to become new methods for the treatment of renal cell carcinoma. This article aims to review the research progressions of PD?1/PD?L1 im?mune checkpoint inhibitors in renal cell carcinoma and explore the possible molecular mechanisms.
Keywords：Renal cell carcinoma( RCC)Programmed cell death factor 1( PD?1)Programmed cell death factor ligand 1( PD?L1)Immune checkpoint inhibitors
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 75-80 )